BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell MobilizationPRNewsWire • 03/03/22
BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid TumorsPRNewsWire • 01/24/22
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma PatientsPRNewsWire • 01/18/22
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & ExpositionPRNewsWire • 12/17/21
BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB)PRNewsWire • 12/15/21
BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/18/21
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 11/18/21
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & ExpositionPRNewsWire • 11/04/21
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell MobilizationPRNewsWire • 10/13/21
BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/18/21
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 08/18/21
BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/26/21
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 05/26/21
BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatmentMarket Watch • 05/04/21
BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma PatientsBenzinga • 05/04/21
BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma PatientsPRNewsWire • 05/04/21